Vitamin E TPGS modified liposomes enhance cellular uptake and targeted delivery of luteolin: An in vivo/in vitro evaluation

Li, Jinli; Cheng, Xudong; Chen, Yan; He, Weiming; Ni, Li; Xiong, Ping; Wei, Minggang

doi:10.1016/j.ijpharm.2016.08.037

Cited by 79 publications

(42 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Briefly, the first formula was prepared by mixing 10% v/v of oil (0.5 ml) and 90% v/v of emulsifier (4.5 µl of emulsifier mixture containing different ratios, such as 1:1, 1:2, 2:1 of emulsifier:co-emulsifier). Alternative formulations were prepared with increasing volumes of oils (20,30,40 and 50% v/v) and decreasing volumes of emulsifier mixtures (80, 70, 60, 50% v/v). A fixed amount of luteolin (10 mg/ml) was incorporated in all mixtures and vortexed for 60 s to prepare luteolin-loaded preconcentrate of SNEDDS.…”

Section: Development Of Sneddsmentioning

confidence: 99%

“…Nanofabrication and nano-encapsulations have also been reported with enhanced solubility, bioavailability and efficacy of luteolin. For instance, nanoencapsulation of luteolin in liposomes [38][39][40][41], micelles [42][43][44][45] and nanoparticles [46] were reported to improve solubility/bioavailability and efficacy as compared to pure luteolin. Self-nanoemulsifying drug delivery systems (SNEDDS) are promising carriers for the delivery of poorly water-soluble drugs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Formulation, characterization, in vitro and in vivo evaluations of self-nanoemulsifying drug delivery system of luteolin

Ansari

Alshetaili

Aldayel

et al. 2020

Journal of Taibah University for Science

View full text Add to dashboard Cite

The purpose of this study was to develop a self-nanoemulsifying drug delivery system (SNEDDS) for the improvement of solubility and bioavailability of luteolin in order to enhance its therapeutic benefits. Formulations were prepared by spontaneous emulsification method which involved low energy mixing of appropriate amounts ofcastor oil, kolliphor & polyethylene glycol 200. The developed formulae were optimized and characterized for self-nanoemulsifying capacity, thermodynamic stability, size behaviour and solubility. The globule size of the optimized formula F1-A1:1 was 112 ± 15 nm, with narrow PDI (0.31 ± 0.09) and good zeta potential (−16.2 ± 3.2 mV). The optimized formula exhibited approximately 83, 17 and 3-fold enhancement in the solubility in vitro release and ex vivo permeation respectively. The luteolin SNEDD exhibited better antioxidant activity (DPPH scavenging activity) than ascorbic acid. Per cent inhibition in rat paw oedema by the SNEDDS formulation was statistically significant when compared with luteolin suspension at equivalent dose (P < 0.05).

show abstract

Section: Development Of Sneddsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Formulation, characterization, in vitro and in vivo evaluations of self-nanoemulsifying drug delivery system of luteolin

Ansari

Alshetaili

Aldayel

et al. 2020

Journal of Taibah University for Science

View full text Add to dashboard Cite

show abstract

“…The therapeutic effect of drug‐loaded liposomes is strongly influenced by drug accumulation inside tumor cells. Hence, cellular uptake is a critical factor for liposomal drug delivery systems . Using flow cytometry and fluorescence microscopy, we showed that the fluorescence intensity of RPV‐modified epirubicin and dioscin co‐delivery liposomes was stronger than that of other liposomes, indicating that A549 cellular uptake of these liposomes was improved after being modified with RPV (Figure A‐E).…”

Section: Discussionmentioning

confidence: 97%

RPV‐modified epirubicin and dioscin co‐delivery liposomes suppress non‐small cell lung cancer growth by limiting nutrition supply

et al. 2020

View full text Add to dashboard Cite

| 621 wileyonlinelibrary.com/journal/cas | INTRODUC TI ONLung cancer is one of the most common malignancies and a leading cause of cancer-related death worldwide. 1 Among all lung cancers, approximately 85% are non-small cell lung cancer (NSCLC), for which morbidity is significantly higher than for small cell lung cancer. 2 In the past decade, targeted therapy, immunotherapy, and similar approaches rapidly developed to become the new treatment modalities for NSCLC. Despite recent developments and improvements in diagnosis and treatment, prospects for patients with NSCLC are dismal and the 5-year overall survival rate is only 15%-18%. 3,4 Rapid growth and metastasis are basic biological characteristics of malignant tumors, including NSCLC. 5 It is well known that angiogenesis plays a key role in cancer growth and metastasis. Anti-angiogenesis treatment has evolved to achieve encouraging results, but despite the widespread application of anti-angiogenic drugs, they have not attained satisfactory efficacy. [6][7][8] This means that alternative nutrient supply channels support tumor growth.Vasculogenic mimicry (VM) is defined as formation of vascu- lar-like structures lined with tumor cells without the presenceThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. AbstractChemotherapy for non-small cell lung cancer (NSCLC) is far from satisfactory, mainly due to poor targeting of antitumor drugs and self-adaptations of the tumors.Angiogenesis, vasculogenic mimicry (VM) channels, migration, and invasion are the main ways for tumors to obtain nutrition. Herein, RPV-modified epirubicin and dioscin co-delivery liposomes were successfully prepared. These liposomes showed ideal physicochemical properties, enhanced tumor targeting and accumulation in tumor sites, and inhibited VM channel formation, tumor angiogenesis, migration and invasion. The liposomes also downregulated VM-related and angiogenesis-related proteins in vitro. Furthermore, when tested in vivo, the targeted co-delivery liposomes increased selective accumulation of drugs in tumor sites and showed extended stability in blood circulation. In conclusion, RPV-modified epirubicin and dioscin co-delivery liposomes showed strong antitumor efficacy in vivo and could thus be considered a promising strategy for NSCLC treatment. K E Y W O R D Sangiogenesis, cell-penetrating peptide, co-delivery liposome, non-small cell lung cancer, vasculogenic mimicry

show abstract

“…The equation for EE of GB or borneol in GGB-LP is as follows:

where W in is the amount of GB or borneol entrapped, and W total is the total amount of GB or borneol used in the preparation [ 32 ].…”

Section: Methodsmentioning

confidence: 99%

Optimization of the Preparation Conditions of Borneol-Modified Ginkgolide Liposomes by Response Surface Methodology and Study of Their Blood Brain Barrier Permeability

Yang

Wang

et al. 2018

Molecules

View full text Add to dashboard Cite

Ginkgolides (GG), containing ginkgolide A (GA), ginkgolide B (GB) and ginkgolide C (GC), are mainly prescribed for ischemic stroke and cerebral infarction. However, the ginkgolides can hardly pass the blood-brain barrier (BBB) into the brain. The purpose of this study was to prepare borneol-modified ginkgolides liposomes (GGB-LPs) to study whether borneol could enhance the transport of ginkgolides across the BBB. The preparation conditions of GGB-LPs were optimized by a response surface-central composite design. Also, pharmacokinetics and biodistribution studies of GGB-LPs were conducted using UPLC-MS. The optimal preparation conditions for GGB-LP were as follows: ratio of lipid to drug (w/w) was 9:1, ratio of phospholipid to cholesterol (w/w) was 7:1, and hydrate volume was 17.5 mL. Under these conditions, the GGB-LP yield was 89.73 ± 3.45%. With GGB-LPs, borneol significantly promoted the transport of ginkgolide across the BBB. The pharmacokinetic parameters of GGB-LP were significantly improved too, with Tmax of 15 min and a high drug concentration of 3.39 μg/g in brain. Additionally, the drug targeting index and relative uptake rate of GGB-LP was increased. Borneol-modified ginkgolide liposomes can thus potentially be used to improve the BBB permeability of gingkolide formulations.

show abstract

Vitamin E TPGS modified liposomes enhance cellular uptake and targeted delivery of luteolin: An in vivo/in vitro evaluation

Cited by 79 publications

References 52 publications

Formulation, characterization, in vitro and in vivo evaluations of self-nanoemulsifying drug delivery system of luteolin

Formulation, characterization, in vitro and in vivo evaluations of self-nanoemulsifying drug delivery system of luteolin

RPV‐modified epirubicin and dioscin co‐delivery liposomes suppress non‐small cell lung cancer growth by limiting nutrition supply

Optimization of the Preparation Conditions of Borneol-Modified Ginkgolide Liposomes by Response Surface Methodology and Study of Their Blood Brain Barrier Permeability

Contact Info

Product

Resources

About